Safety and outcome in patients with AHA treated with emicizumab
| Outcome parameters . | Median . | IQR . | Range . |
|---|---|---|---|
| Breakthrough bleedings after FVIII:h >5% | 0 | 0-0 | |
| Day ELISA <30 AU/mL (n = 5) | 176 | 123-216 | 61-325 |
| Days on ICU (n = 1) | 3 | 3-3 | 3-3 |
| Days in hospital | 9.5 | 7-21 | 5-53 |
| Overall survival day 28 | 92% | ||
| Deaths* | 1 (day 82) |
| Outcome parameters . | Median . | IQR . | Range . |
|---|---|---|---|
| Breakthrough bleedings after FVIII:h >5% | 0 | 0-0 | |
| Day ELISA <30 AU/mL (n = 5) | 176 | 123-216 | 61-325 |
| Days on ICU (n = 1) | 3 | 3-3 | 3-3 |
| Days in hospital | 9.5 | 7-21 | 5-53 |
| Overall survival day 28 | 92% | ||
| Deaths* | 1 (day 82) |
Medians, IQR, range; n = 12.
ELISA, enzyme-linked immunosorbent assay; ICU, intensive care unit.
Cause of death: peritonitis.